Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine; tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine - film coated tablet - 10 mg - active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax red spectraspray acsl0673 erythrosine gelatin hypromellose magnesium stearate maize starch propylene glycol shellac sucrose active: tranylcypromine sulfate 13.68mg equivalent to 10 mg tranylcypromine excipient: calcium sulfate carnauba wax erythrosine gelatin magnesium stearate maize starch opadry red 06h250000 sucrose - parnate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of anti-depressants has failed. it is not recommended for use in mild depressive states resulting from temporary situational difficulties.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine;   - film coated tablet - 1 mg - active: trifluoperazine hydrochloride 1.18mg equivalent to 1 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine;   - film coated tablet - 2 mg - active: trifluoperazine hydrochloride 2.36mg equivalent to 2 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

boucher & muir (nz) ltd t/a mercury pharma (nz) - trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine;   - film coated tablet - 5 mg - active: trifluoperazine hydrochloride 5.9mg equivalent to 5 mg trifluoperazine   excipient: calcium sulfate dihydrate gelatin maize starch opadry blue oy-4492 purified talc purified water as solvent stearic acid sucrose - chronic therapy in high doses for management of manifestations of psychotic disorders, such as acute and chronic catatonic hebephrenic and paranoid schizophrenia, psychosis due to organic brain damage, toxic psychosis, manic depressive psychosis, senile psychosis and mental deficiency. short-term therapy treatment of acute alcoholism for the relief of delusons, hallucinations and confused state, and for the control of accompanying tremulousness and aggressive behaviour. in low doses to control excessive anxiety, tension and agitation as seen in neuroses or associated with somatic conditions. stelazine is not recommended as first line therapy in patients with non-psychotic anxiety disorders, nor should therapy be carried out for more than 12 weeks. for nausea and vomiting of various causes.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 0.5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - baclofen, quantity: 50 microgram/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - sintetica baclofen intrathecal is indicated in patients with severe chronic spasticity of spinal origin (associated with injury, multiple sclerosis, or other spinal cord diseases) or of cerebral origin who are unresponsive to orally administered antispastics (including oral baclofen) and/or who experience unacceptable side effects at effective oral doses.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - orlistat, quantity: 120 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; sodium starch glycollate type a; hydrophobic colloidal silica anhydrous; microcrystalline cellulose; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin - prolistat is indicated for the treatment of obese patients with a body mass index (bmi) ? 30, and overweight patients with a bmi ? 27 in the presence of other risk factors, in conjunction with a mildly hypocaloric diet.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - clindamycin hydrochloride, quantity: 162.87 mg (equivalent: clindamycin, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; purified talc; titanium dioxide; indigo carmine; sorbitan monolaurate; gelatin; sodium lauryl sulfate; carmoisine; patent blue v - clindamycin bnm (clindamycin hydrochloride) capsules are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.,clindamycin bnm capsules are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci and staphylococci. ,its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. ,anaerobes serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and skin structure infections; septicaemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, non-gonococcal tubo-ovarian abscess, pelvic cellulitis and post-surgical vaginal cuff infection. ,streptococci serious respiratory tract infections; serious skin and skin structure infections, septicaemia. ,staphylococci serious respiratory tract infections; serious skin and skin structure infections; septicaemia; acute haematogenous osteomyelitis. ,pneumococci serious respiratory tract infections. ,adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. indicated surgical procedures should be performed in conjunction with antibiotic therapy. ,bacteriological studies should be performed to determine the causative organisms and their susceptibility to clindamycin.